DRIL-QUIP Form 4											
June 05, 200	1 /			GECUD				NCEO			PPROVAL
		IEDS	SIAIES					NGE C	OMMISSION	OMB Number:	3235-0287
Washington, D.C. 20549Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations 					January 31, 2005 Estimated average burden hours per response 0.5						
(Print or Type I	Responses)										
1. Name and A REIMERT		porting I	Person [*]	Symbol	Name and		Tradii	ng	5. Relationship of Issuer		
(Last)	(First)	(N	(liddle)		Earliest Tr				(Check	k all applicable)
13550 HEM	IPSTEAD	HIGHV	WAY	(Month/D 06/01/20	-				X Director X Officer (give below) Co-Chai	title $X_10\%$ title M_2 Other below)	er (specify
HOUSTON	(Street) , TX 7704()			ndment, Da hth/Day/Year	-	1		6. Individual or Jo Applicable Line) Form filed by O _X_ Form filed by M Person	ne Reporting Per	son
(City)	(State)		(Zip)	Tabl	e I - Non-D	erivative	Secur	ities Acqu	uired, Disposed of	, or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transacti (Month/Day		Execution any	ned n Date, if	3. Transactic Code (Instr. 8) Code V	4. Securi m(A) or Di (Instr. 3,	ties A	cquired d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial
Common Stock	06/04/200)7			S	100	D	\$ 49.15	3,498,015 <u>(1)</u>	Ι	See footnote (2)
Common Stock	06/04/200)7			S	400	D	\$ 49.18	3,497,615	Ι	See footnote (2)
Common Stock	06/04/200)7			S	1,820	D	\$ 49.2	3,495,795	I	See footnote (2)
Common Stock	06/04/200)7			S	2,080	D	\$ 49.21	3,493,715	Ι	See footnote

Common Stock

910 D

(2)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	5. onNumber of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		ate	Secur	int of rlying	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owna Follo Repo Trans (Instr
			Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address			Relationships	
	Director	10% Owner	Officer	Other
REIMERT LARRY E 13550 HEMPSTEAD HIGHWAY HOUSTON, TX 77040	Х	Х	Co-Chairman of the Boa	ard
Reimert Family Partners, Ltd. 13550 HEMPSTEAD HIGHWAY X HOUSTON, TX 77040				
Signatures				
/s/ Larry E. Reimert				06/05/2007
<u>**</u> Signature of	Reporting Pe	erson		Date
/s/ Larry E. Reimert, Managing General Partner, Reimert Family Partners, Ltd.			06/05/2007	
**Signature of Reporting Person				Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This is the sixth of six Forms 4 filed by the reporting person to report transactions that occurred on June 1, 2007 and June 4, 2007. The six forms should be read together.
- The shares of Common Stock sold were owned and sold directly by Reimert Family Partners, Ltd., and indirectly by Larry E. Reimert as
- (2) managing general partner of Reimert Family Partners, Ltd. The remaining shares of Common Stock are owned by Reimert Family Partners, Ltd. Mr. Reimert disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number. TEXT-INDENT: 0px" align="right">41,195,842

4

Election of Mr Christopher Viehbacher

3,849,501,839

99.49

19,772,868

0.51

3,869,274,707

79,609,728

5

6

Election of Professor Sir Roy Anderson

3,909,528,117

99.82

7,050,023

0.18

3,916,578,140

32,306,295

Re-election of Sir Christopher Gent

3,810,072,560

		98.08
		74,773,259
		1.92
		3,884,845,819
		64,038,616
	7	
Re-election of Sir Ian Prosser		
		3,907,565,196
		99.77
		9,050,718
		0.23
		3,916,615,914
		32,268,521
	8	
Re-election of Dr Ronaldo Schmitz	Ŭ	
		3,899,485,674
		99.56
		17,139,141
		0.44
		3,916,624,815
		32,259,620
	9	
Re-appointment of Auditors		
		3,877,708,481
		99.54
		17,936,334
Explanation of Responses		Λ

	0.46
	3,895,644,815
	53,239,620
10	
Remuneration of Auditors	
	3,913,134,400
	99.69
	12,121,289
	0.31
	3,925,255,689
	23,628,746
11	
To authorise the company to make donations to Political Organisations & incur Political Expenditure	
	3,764,947,848
	97.09
	112,911,635
	2.91
	3,877,859,483
	71,024,952
12	
Authority to allot shares	
	3,877,961,825
	98.44
	61,623,083
	1.56

3,939,584,908

	9,299,527
13	
Disapplication of pre-emption rights***	
	3,891,091,851
	98.82
	46,291,865
	1.18
	3,937,383,716
	11,500,719
14	
Authority for the Company to purchase its own shares ***	
	3,871,222,137
	98.23
	69,853,695
	1.77
	3,941,075,832
	7,808,603
15	
Adopt new Articles of Association ***	
	3,919,473,970
	99.55
	17,602,044
	0.45
	3,937,076,014
	11,808,421

Notes:

* Includes discretionary votes.

** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

*** Indicates Special Resolutions requiring a 75% majority

The following table provides further relevant information:

	GlaxoSmithKline's Eighth AGM S (2008)	GlaxoSmithKline's Seventh AGM (2007)
Issued share capital (excluding Treasury Shares)	5,352,175,102	5,725,158,425
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)	73.78%	73.68%
Total shareholder population	172,581	180,486
Total number of proxies lodged	12,896	14,357
% of shareholders who lodged proxies	7.47%	7.95%
Number of shareholders, corporate representatives and proxies who attended the AGM	266	276

S M Bicknell Company Secretary 21 May 2008

These results will shortly be available on the Company's website <u>www.gsk.com</u>.

Enquiries:	UK Media	Philip Thomson Alice Hunt	(020) 8047 5502 (020) 8047 5502
		Gwenan White	(020) 8047 5502
	US Media	Nancy Pekarek	(215) 751 7709
		Mary Anne Rhyne	(919) 483 2839

European Analyst / Investor

	David Mawdsley Sally Ferguson Gary Davies	(020) 8047 5564 (020) 8047 5543 (020) 8047 5503
US Analyst / Investor	Frank Murdolo Tom Curry	(215) 751 7002 (215) 751 5419

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc (Registrant)

Date: May 21, 2008

By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc